Menu
Memory Treatment Centers of Bonita Springs specializes in the treatment of Alzheimer’s Disease and other forms of Dementia. We use the latest advancements in medical science to provide cutting-edge treatment to our patients while empowering them to take control of their healthcare decisions. We are committed to providing compassionate and comprehensive care to improve your quality of life and extend your independence.
Our team is comprised of experienced and dedicated healthcare professionals who are passionate about providing personalized care to patients. We understand that the needs of our patients and their loved ones are unique. As a result, our care team tailors treatment plans to suit the individual, while providing support for their loved ones. These treatment plans are developed with the guidance of the latest research and by adopting a holistic perspective that acknowledges the interplay between physical and mental well-being.
Furthermore, we are proud to work with families and caregivers to provide education and support, ensuring that our patients receive the best care possible.
Bonita Springs
28420 Bonita Crossings Blvd
Suite 110
Bonita Springs, FL 34135
T: 239-235-0380
F: 1-239-237-5574
Hours
Monday-Thursday
8:00 a.m. – 5:00 p.m.
Friday
8:00 a.m. – 12:00 p.m.
At Memory Treatment Centers, we are committed to providing compassionate and comprehensive care to improve your quality of life and extend your independence. Through an in-depth diagnostic process using the latest medical technology and advancements, we aim to identify the root cause of cognitive impairments. Once a diagnosis is reached, our care team will develop a comprehensive and holistic treatment plan tailored to your unique diagnosis.
On January 6th, 2023, the FDA granted accelerated approval for Leqembi (Lecanemab) which is the second FDA-approved therapy for Alzheimer’s Disease.
Leqembi (Lecanemab) specifically targets protofibrils which cluster together and forms the protein plaque beta-amyloid 42.
Memory Treatment Centers is now actively infusing Leqembi.
On July 2nd, 2024 the FDA granted full traditional approval for Kisunla (Donanemab) which is the second fully FDA approved therapy for Alzheimer’s disease that specifically targets the protein plaque beta-amyloid 42.
The approval of Donanemab has now allowed healthcare providers like neurologists and neurocognitive specialists, to continue to be proactive with treating and slowing the progression of Alzheimer’s disease.
